Molecular biologist warns of vCJD (variant Creutzfeldt Jakob disease) incidence:
This article was originally published in Clinica
A senior German molecular biologist has warned that Germany could be faced with up to 12 cases of new variant Creuzfeldt Jakob Disease (vCJD) within the next two years. Professor Konrad Beyreuther from the University of Heidelberg bases his estimate on data gathered from vCJD incidence in the UK, but further advises that the disease could manifest itself in Germany in the form of another variant. An extrapolation of UK data shows that Germany could have up to 1,200 BSE-infected cattle.
You may also be interested in...
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.
A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.
It is the question that continues to exercise the minds of management boards in the medtech industry even as digital health care tools become increasingly ingrained in commercial R&D and operations – and in patient treatment pathways.